<img height="1" width="1" style="display:none" src="https://www.facebook.com/tr?id=799546403794687&amp;ev=PageView&amp;noscript=1">

“We would like to believe it is the effect on the MDSCs that is enhancing the efficacy of pembrolizumab in these patients,” researcher Martin D. McCarter, MD, professor of surgical oncology at University of Colorado School of Medicine, told Healio. “We demonstrate some supporting data to suggest this relationship but cannot prove for sure that was the mechanism. For example, it could have been patient selection in a relatively small study.”